April 5, 2005 -- Stocks meandered on Tuesday, moving without a great sense of purpose, though with a generally positive bias. The Centient Biotech 200 moved up .70%, adding on 21 points to close at 3066.95. Biotech did well at the beginning of the day and at the close. In between, it traded on either side of flat. In individual company news, Pfizer guided the street lower for 2005 earnings, but was upbeat overall, giving its stock a trading boost, Avigen will go into cash conservation mode and look for wealthy suitors, EntreMed has a cancer drug that showed efficacy against rheumatoid arthritis in mice, Nastech used RNA interference to inhibit rheumatoid arthritis in the lab, Angiotech said its drug eluting stent has FDA permission to undergo an immediate MRI, Xoma climbed mysteriously during the last half of the day, and Ciphergen lost 25% on a Q1 sales shortfall. More details...
